Onyx™ Liquid Embolic IDE Clinical Study

NCT06742801

Status	RECRUITING
Phase	Not Applicable
Sponsor	Medtronic Endovascular
Enrollment	119 participants

Key Eligibility Criteria

Inclusion (6)

- Patient is e 22 years old.
- Active arterial bleeding in the peripheral vasculature confirmed by radiologic and/or endoscopic imaging and deemed suitable for embolization treatment by the investigator.
- In this study, peripheral vasculature is defined as outside the brain and heart.
- Patient or legally authorized representative (LAR) is able to provide written consent to participate in the study.
- Life expectancy of \>30 days, in the opinion of the investigator at the time of enrollment.

... and 1 more (see full listing online)

Exclusion (7)

- Pregnant or breastfeeding.
- Symptoms of active infection.
- Patient is known to be participating in the study of an investigational drug, biologic, or device.
- Contrast allergy or other contraindication to angiography, CT, or catheterization, including contrast sensitivity that cannot be adequately treated prior to index procedure.
- Known allergy to components of Onyx™.

... and 2 more (see full listing online)

Locations (14 total)

Mayo Clinic, Phoenix, Arizona, United States
University of California, Irvine, Irvine, California, United States
Stanford Medical Center, Palo Alto, California, United States
... and 11 more locations